Praxis Performance Studio is raising $350,000 to fund the construction and activation of our Phase II Clinical Sanctuary at 625 Fair Oaks Ave, South Pasadena — a premier medical corridor location.
Allocation Amount Purpose
────────────────────────────────────────────────────────────
Clinical Build-Out $160,000 Phase II Sanctuary at 625
Fair Oaks — studio build-out,
clinical environment, HVAC,
electrical, plumbing
Diagnostic Tech Stack $ 49,955 Calivus Labs Moti Physio,
InBody 970, Vald Force Plates
Operating Reserves $140,045 6-month operating runway
bridging Phase I → Phase II
────────────────────────────────────────────────────────────
TOTAL $350,000
Pre-Revenue Validation: 35 pre-qualified intakes (87% of initial capacity) generated entirely through physician referral — zero marketing spend
Recurring Revenue Model: 12-month subscription contracts at $1,500/client/month create predictable, high-visibility cash flow
Zero Customer Acquisition Cost: 100% physician-referred pipeline eliminates the #1 cost that kills traditional fitness businesses
5.5x Debt Service Coverage: At 87% capacity utilization, projected cash flow covers debt obligations at 5.5x
Depreciable Asset Base: ~$50K in diagnostic equipment provides tangible collateral and accelerated depreciation benefits
Corridor Lock-In: First-mover advantage in the Pasadena–South Pasadena medical corridor with no direct competitors
Instrument: Revenue Share Agreement
Total Raise: $350,000
Minimum Investment: $25,000
Repayment Multiple: 1.5× ($1.50 returned per $1.00 invested)
Revenue Share Rate: 10% of monthly gross revenue,
distributed pro-rata to all investors
until the 1.5× multiple is returned
Estimated Repayment: 24–30 months at projected capacity
Repayment Commencement: First full calendar month following
Phase II activation
Security: Senior claim on practice revenue;
subordinated lien on diagnostic
equipment
Reporting: Quarterly financial statements and
clinical utilization reports delivered
to all investors of record
Investor Communication: Quarterly investor update letter from
the Practitioner-in-Residence
Phase Location Status
────────────────────────────────────────────────────────────
Phase I: Pilot Lab 117 W Bellevue Dr #4, Active
Pasadena (Reflex Perf.)
Phase II: Sanctuary 625 Fair Oaks Ave, Funded by
South Pasadena this raise
Phase III: Campus TBD — Pasadena medical 5-year
corridor horizon
Praxis Performance is engineered for institutional integration. Our 10-year roadmap focuses on deep-tier data collaboration with regional healthcare leaders, transitioning from a clinical referral partner to a co-branded performance utility. We aren't just scaling a studio; we are scaling a new standard of care.
Prospective investors should consider the following:
Single-Operator Risk: Praxis Performance currently relies on a sole practitioner. Business continuity planning and practitioner expansion are priorities as the business scales
Facility Dependency: The Phase II Sanctuary requires construction and permitting. Timelines are subject to municipal approval. The Phase I Pilot Lab provides operational continuity during build-out
Market Risk: Revenue projections are based on pre-qualified intakes that have not yet converted to paying subscriptions
Regulatory Risk: Any regulatory reclassification of metabolic coaching services could impact operations
Concentration Risk: Revenue is concentrated in a single geographic market and a single service model
This site contains forward-looking statements regarding projected revenue, capacity utilization, and business expansion. These projections are based on current pre-launch data and reasonable assumptions. Actual results may differ materially. This is not an offer to sell securities and is intended for informational purposes only. Prospective investors should consult their own legal and financial advisors.
If you are considering participation in the Praxis Performance Studio Series Seed, we invite you to request a confidential Investor Briefing.
During the briefing, you will receive a full review of the Revenue Share Agreement, operating projections, and the opportunity to ask questions directly of the Practitioner-in-Residence.
Accepting commitments through Q3 2026 — allocation is limited to 14 investors at $25,000 minimum
→ Request an Investor Briefing
This is not a commitment to invest. All inquiries are confidential.